ClinicalTrials.gg
RecruitingNCT06719583BLAAC PDUpdated Feb 27, 2026

Black and African Americans Connections to Parkinson's Disease (BLAAC PD)

An observational study in Parkinson Disease, sponsored by Michael J. Fox Foundation for Parkinson's Research. Recruiting at 12 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Michael J. Fox Foundation for Parkinson's Research · Observational

From the registry’s dates

  • Started Nov 2020; still recruiting 5 years 11 months later.
Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Study summary

BLAAC PD is a research study to understand what Parkinson's disease looks like for Black and African American communities.

BLAAC PD is happening at research centers around the United States. The study is part of the Global Parkinson's Genetics Program (GP2). GP2 is a research project working to transform understanding of the genetics of Parkinson's disease and make that knowledge globally relevant.

Read the detailed description

Research studies have found connections between genes and Parkinson's disease (PD). But those results have mostly come from studies with non-Black or African American volunteers. BLAAC PD aims to learn more about gene changes that may cause Parkinson's in Black and African American people. Study volunteers at sites across the United States will attend one visit and will give either a blood or saliva sample, complete a smell test, and may be asked to complete a physical exam. This new data could lead to future Parkinson's tests and treatments for Black and African American people and it may help better understand disease in other groups, too.

This pioneering initiative will fill a gap of knowledge about PD in Black and African American people.

02

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • genetics
  • underrepresented
03

In context

Parkinson Disease

4,573 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 96 across 1,085 observational studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

Michael J. Fox Foundation for Parkinson's Research is the lead sponsor of 16 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Black Americans and African Americans with Parkinson's Disease or without a history of Parkinson's (control volunteers).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to provide
  • Age 50 years or older
  • Self-identify as Black or African American

Exclusion criteria

Exclusion Criteria for Control Participants:

  • Diagnosis of Parkinson's Disease and/or neurological condition
  • Familial history of PD and/or neurodegenerative or psychiatric conditions
  • Unknown family history of PD and/or neurodegenerative or psychiatric conditions
  • Any conditions that, in the investigator's opinion, preclude the individual's ability to carry out study activities
  • If submitting a saliva sample, nothing by mouth (food, drink, gum, tobacco, or smoking) for 30 minutes prior to sample collection

Inclusion Criteria for Participants with a Diagnosis of PD:

  • Ability to provide
  • Age 18 years or older
  • Self-identify as Black or African American
  • Meet the Movement Disorder Society's clinical diagnostic criteria for Parkinson's disease

Exclusion Criteria for Participants with a Diagnosis of PD:

- If submitting a saliva sample, nothing by mouth (food, drink, gum, tobacco, or smoking) for 30 minutes prior to sample collection

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
2,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Participants with Parkinson's Disease

    Data collected from these participants include demographic information and family health history. Participants may also complete a physical exam. Participants also complete a smell test and contribute a blood or saliva sample for genetic analyses.

  • Control Participants

    Data collected from these participants include demographic information and family health history. Participants also complete a smell test and contribute a blood or saliva sample for genetic analyses.

06

What researchers measure

Primary outcomes

  1. Explore novel risk factors and characterization

    To explore novel risk factors and characterization of known genetic risk factors contributing to Parkinson's disease risk in the Black and African American population.

    Time frame: 5 years

07

Study locations

11 of 12 sites recruiting
08

References and documents

Publications

  • Chahine LM, Louie N, Solle J, Akcimen F, Ameri A, Augenbraun S, Avripas S, Breaux S, Causey C, Chandra S, Dean M, Disbrow EA, Fanty L, Fernandez J, Foster ER, Furr Stimming E, Hall D, Hinson V, Johnson-Turbes A, Jonas C, Kilbane C, Norris SA, Nguyen BT, Padmanaban M, Paquette K, Parry C, Pessoa Rocha N, Rawls A, Shamim EA, Shulman LM, Sipma R, Staisch J, Traurig R, von Coelln R, Wild Crea P, Xie T, Fang ZH, O'Grady A, Kopil CM, McGuire Kuhl M, Singleton A, Blauwendraat C, Bandres-Ciga S; BLAAC PD Study and the Global Parkinson's Genetics Program (GP2). The Black and African American Connections to Parkinson's Disease (BLAAC PD) study protocol. BMC Neurol. 2024 Oct 21;24(1):403. doi: 10.1186/s12883-024-03914-7. PubMed 39434044 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06719583
Lead sponsor
Michael J. Fox Foundation for Parkinson's Research
Responsible party
Sponsor
First posted
Dec 6, 2024
Start date
Nov 16, 2020
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 27, 2026

Study contacts

Naomi Louie, MPH RDN
Contact
nlouie@michaeljfox.org
212-509-0995 ext. 354
Lana Chahine, MD, PhD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion